With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro
You may also be interested in...
Mylan And India’s Biocon Team Up To Develop Insulin Biosimilars Of Sanofi, Lilly, Novo Nordisk Products
Less than a year after Pfizer broke out of a deal with Biocon, the company announced it is linking up with Mylan to make biosimilars of insulin products made by Sanofi, Lilly and Novo Nordisk.
Post Biocon, Pfizer Pushes Forward On Biosimilar MABs
Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.
Pfizer’s Biosimilar Program: A MAB Dash After Biocon Deal Ends
Following the breakup in March of its insulin biosimilars deal with Biocon, Pfizer confirms plans to develop monoclonal antibody biosimilars on its own, and has put its first candidate, rituximab, into Phase 1 testing.